Medical News Today: Strawberries may reduce gut inflammation
According to a recent study, less than one cup of strawberries per day could reduce the distressing symptoms of inflammatory bowel disease.
Publication date: Available online 6 April 2020Source: Chemico-Biological InteractionsAuthor(s): Bo Dou, Wenji Hu, Minkai Song, Robert J. Lee, Xiaoyu Zhang, Di Wang
MONDAY, April 6, 2020 -- Older age is associated with an increased risk for bacteremia in hospitalized patients with inflammatory bowel disease (IBD), according to a study published in the March issue of the United European Gastroenterology...
Day 1,364 of the COVID-19 quarantine (well, at least it feels like it). How are you holding up? If you’re like most people, you’re not having much fun. But if you already struggle with anxiety, depression or another mental health issue, these days of isolation and uncertainty can feel like absolute torture. In today’s Not Crazy episode, Gabe laments the loss of his routine — those regular activities he clung to religiously to keep his mental health in check. Now what is he supposed to do? Tune in for a special quarantine episode. Together, we will grieve our old routines and discuss...
This review describes the principles and process followed to define the target therapeutic ranges for infliximab and adalimumab in the treatment of inflammatory bowel disease.Alimentary Pharmacology &Therapeutics
Publication date: Available online 5 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Katarína Maráková, Juraj Piešťanský, Zuzana Zelinková, Peter Mikuš
: The relationship between exclusive enteral nutrition (EEN) and bone status is poorly defined in pediatric Crohn disease (CD).
The article Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study, written by Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning and Rita L. Hui, was originally published electronically on 26 February 2020 without open access.
A substantial proportion patients with inflammatory bowel disease (IBD) have a primary non-response to infliximab; markers are needed to identify patients most likely to respond to treatment. We investigated whether production of tumor necrosis factor (TNF) by peripheral blood mononuclear cells (PBMCs) can be used as a marker to predict response.
ConclusionNon-adherence to mesalamine was underestimated by physicians in pregnant UC patients and contributed to disease relapse and possibly on pregnancy outcomes. Preconceptional education regarding safety of medications and risk of self-discontinuation is warranted.